Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study

被引：0
|
作者：
Huang, C. [1 ,2 ]
Yang, Y. [3 ,4 ]
Kwong, A. [5 ]
Chen, S-C. [6 ]
Tseng, L-M. [7 ]
Liu, M-C. [8 ]
Shen, K. [9 ]
Wang, S. [10 ]
Ng, T-Y. [11 ]
Feng, Y. [12 ]
Sun, G. [12 ]
Yan, I. R. [12 ]
Shao, Z. [13 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[3] China Med Univ, Taichung Vet Gen Hosp, Taipei, Taiwan
[4] China Med Univ, Sch Med, Taipei, Taiwan
[5] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Peoples R China
[6] Chang Gung Med Fdn, Div Gen Surg, Taipei, Taiwan
[7] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan
[8] Koo Fdn Sun Yat sen Canc Ctr, Oncol, Taipei, Taiwan
[9] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China
[10] Sun Yat Sen Univ, Canc Ctr, Med Oncol, Guangdong Sheng, Peoples R China
[11] Tuen Mun Hosp, Clin Oncol, Hong Kong, Peoples R China
[12] Roche China Holding Ltd, PDO, Shanghai, Peoples R China
[13] Fudan Univ, Shanghai Canc Ctr, Breast Surg, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1O
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Safety of trastuzumab emtansine (T-DM1) in HER2-positive advanced breast cancer (BC) patients (pts): Primary results from KAMILLA study cohort 1.
    Barrios, Carlos H.
    Wuerstlein, Rachel
    Anton, Antonio
    Delaloge, Suzette
    Montemurro, Filippo
    Bonneterre, Jacques
    Quenel-Tueux, Nathalie
    Linn, Sabine C.
    Button, Peter
    Lindegger, Nicolas
    Ellis, Paul Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development
    Fujihara, Miwa
    Shien, Tadahiko
    Shien, Kazuhiko
    Suzawa, Ken
    Takeda, Tatsuaki
    Zhu, Yidan
    Mamori, Tomoka
    Otani, Yusuke
    Yoshioka, Ryo
    Uno, Maya
    Suzuki, Yoko
    Abe, Yuko
    Hatono, Minami
    Tsukioki, Takahiro
    Takahashi, Yuko
    Kochi, Mariko
    Iwamoto, Takayuki
    Taira, Naruto
    Doihara, Hiroyoshi
    Toyooka, Shinichi
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [33] Trastuzumab Emtansine (T-DM1): No radiosensitizing effect in vitro on HER2-positive breast cancer cells (study in vitro)
    Mignot, Fabien
    Kirova, Youlia
    Verrelle, Pierre
    Teulade-Fichou, Marie-Paule
    Megnin-Chanet, Frederique
    CANCER RESEARCH, 2020, 80 (04)
  • [34] Trastuzumab Emtansine (T-DM1) Plus S-1 in Patients with Trastuzumab-Pretreated HER2-Positive Advanced or Metastatic Breast Cancer: A Phase Ib Study
    Kojima, Yasuyuki
    Yoshie, Reiko
    Kawamoto, Hisanori
    Shimo, Arata
    Uejima, Tomoko
    Iwatani, Tsuguo
    Motoyoshi, Ai
    Kanemaki, Yoshihide
    Boku, Narikazu
    Tsugawa, Koichiro
    ONCOLOGY, 2019, 96 (06) : 309 - 317
  • [35] The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
    Peipei Liu
    Jiajun Fan
    Ziyu Wang
    Wenjing Zai
    Ping Song
    Yongping Li
    Dianwen Ju
    AMB Express, 10
  • [36] Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy
    Molinelli, Chiara
    Parisi, Francesca
    Razeti, Maria Grazia
    Arecco, Luca
    Cosso, Maurizio
    Fregatti, Piero
    Del Mastro, Lucia
    Poggio, Francesca
    Lambertini, Matteo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 241 - 250
  • [37] The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
    Liu, Peipei
    Fan, Jiajun
    Wang, Ziyu
    Zai, Wenjing
    Song, Ping
    Li, Yongping
    Ju, Dianwen
    AMB EXPRESS, 2020, 10 (01)
  • [38] In vitro effects of Trastuzumab Emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells
    Mignot, F.
    Kirova, Y.
    Verrelle, P.
    Teulade-Fichou, M-P
    Megnin-Chanet, F.
    CANCER RADIOTHERAPIE, 2021, 25 (02): : 126 - 134
  • [39] Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
    Sarika Jain
    Ami N. Shah
    Cesar A. Santa-Maria
    Kalliopi Siziopikou
    Alfred Rademaker
    Irene Helenowski
    Massimo Cristofanilli
    William J. Gradishar
    Breast Cancer Research and Treatment, 2018, 171 : 371 - 381
  • [40] Cost-effectiveness of trastuzumab emtansine (T-DM1) for HER2-positive advanced breast cancer (ABC)
    Quang Anh Le
    Bae, Yuna
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345